Nesiritide atrial natriuretic peptide  

Natrecor - Brain Natriuretic Peptide 32 - Brain Natriuretic Peptide-32 - Natriuretic Factor 32 - Natriuretic Factor-32 - Natriuretic Peptide Type B - Natriuretic Peptide Type-B - Type B Natriuretic Peptide - Type-B Natriuretic Peptide - BNP Gene Product - B-Type Natriuretic Peptide - Nesiritide - BNP 32 - BNP-32 - Brain Natriuretic Peptide      

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathDeath from any cause or hospitalization for heart failure

acute heart failure  

NSGET (comparative trial), 2000     nesiritidecontrolLow risk of bias remark
NSGET (efficacy trial), 2000     nesiritideplaceboLow risk of bias negative48%
PROACTION, 2003     nesiritideplaceboLow risk of bias negative388%
BNP-CARDS, 2007          NCTnesiritideplaceboLow risk of bias remark
FUSION 2, 2008        NCTnesiritideplaceboLow risk of bias remark
ASCEND-HF, 2011        NCTnesiritideplaceboLow risk of bias negative -10%-7%
VMAC (intravenous neseritide), 2002      NCTnesiritideplaceboLow risk of bias remark
PRECEDENT, 2002      NCTnesiritidedobutamineExploratory remark
VMAC (24h), 2002      NCTnesiritidenitroglycerinRisk of bias negative56%
FUSION 1, 2004    NCTnesiritidestandard careLow risk of bias remark

heart failure  

NSGET (comparative trial), 2000     nesiritidecontrolLow risk of bias remark
NSGET (efficacy trial), 2000     nesiritideplaceboLow risk of bias negative48%
PROACTION, 2003     nesiritideplaceboLow risk of bias negative388%
BNP-CARDS, 2007          NCTnesiritideplaceboLow risk of bias remark
FUSION 2, 2008        NCTnesiritideplaceboLow risk of bias remark
ASCEND-HF, 2011        NCTnesiritideplaceboLow risk of bias negative -10%-7%
VMAC (intravenous neseritide), 2002      NCTnesiritideplaceboLow risk of bias remark
PRECEDENT, 2002      NCTnesiritidedobutamineExploratory remark
VMAC (24h), 2002      NCTnesiritidenitroglycerinRisk of bias negative56%
FUSION 1, 2004    NCTnesiritidestandard careLow risk of bias remark

restenosis after PCI  

PREVENT, 2000     P-32placeboLow risk of bias suggesting∞%
INHIBIT, 2002     P-32placeboLow risk of bias suggesting0%
START, 2000       P-32placeboLow risk of bias suggesting173%